Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

(2010) Michael Crump et al.   LEUKEMIA & LYMPHOMA

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

(2009) R Kumar et al.   BRITISH JOURNAL OF CANCER

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer

(2009) Dimitrios H Roukos et al.   Expert Review of Anticancer Therapy

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies

(2009) Chiung-Ing Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

(2009) Jianbiao Zhou et al.   Journal of Hematology & Oncology

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

(2008) Andrea Camera et al.   ANNALS OF HEMATOLOGY

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia

(2008) S. Hu et al.   MOLECULAR CANCER THERAPEUTICS